Amylyx Pharmaceuticals, Inc. (AMLX)
34.76
-2.42
(-6.51%)
USD |
NASDAQ |
Aug 28, 16:00
35.42
+0.66
(+1.90%)
After-Hours: 20:00
Amylyx Pharmaceuticals Cash from Operations (Quarterly) : -31.42M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.42M |
| March 31, 2026 | -36.88M |
| December 31, 2025 | -27.90M |
| September 30, 2025 | -30.37M |
| June 30, 2025 | -25.25M |
| March 31, 2025 | -39.82M |
| December 31, 2024 | -59.01M |
| September 30, 2024 | -41.57M |
| June 30, 2024 | -66.58M |
| March 31, 2024 | -0.489M |
| December 31, 2023 | 13.55M |
| September 30, 2023 | -5.169M |
| Date | Value |
|---|---|
| June 30, 2023 | 8.609M |
| March 31, 2023 | -5.072M |
| December 31, 2022 | -49.70M |
| September 30, 2022 | -43.08M |
| June 30, 2022 | -46.46M |
| March 31, 2022 | -40.63M |
| December 31, 2021 | -28.24M |
| September 30, 2021 | -20.86M |
| June 30, 2021 | -13.05M |
| March 31, 2021 | -12.64M |
| December 31, 2020 | -8.888M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Pfizer Inc. | 835.00M |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
| EyePoint, Inc. | -62.35M |
| Bristol Myers Squibb Co. | 3.393B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -149.80M |
| Cash from Financing (Quarterly) | 1.479M |
| Free Cash Flow | -130.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2829 |
| Free Cash Flow to Equity (Quarterly) | -31.08M |
| Free Cash Flow to Firm (Quarterly) | -31.45M |
| Free Cash Flow Yield | -3.54% |